Trinity Biotech (TRIB) EBT Margin (2016 - 2024)
Historic EBT Margin for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to 99.62%.
- Trinity Biotech's EBT Margin fell 586300.0% to 99.62% in Q4 2024 from the same period last year, while for Dec 2024 it was 49.92%, marking a year-over-year increase of 150600.0%. This contributed to the annual value of 49.92% for FY2024, which is 150500.0% up from last year.
- Per Trinity Biotech's latest filing, its EBT Margin stood at 99.62% for Q4 2024, which was down 586300.0% from 31.64% recorded in Q3 2024.
- Trinity Biotech's 5-year EBT Margin high stood at 32.18% for Q3 2020, and its period low was 133.93% during Q2 2023.
- In the last 5 years, Trinity Biotech's EBT Margin had a median value of 36.32% in 2024 and averaged 31.97%.
- In the last 5 years, Trinity Biotech's EBT Margin crashed by -1011000bps in 2022 and then soared by 904500bps in 2024.
- Over the past 5 years, Trinity Biotech's EBT Margin (Quarter) stood at 31.4% in 2020, then tumbled by -140bps to 12.44% in 2021, then plummeted by -433bps to 66.32% in 2022, then soared by 38bps to 41.0% in 2023, then crashed by -143bps to 99.62% in 2024.
- Its last three reported values are 99.62% in Q4 2024, 31.64% for Q3 2024, and 43.48% during Q2 2024.